Summary: Duloxetine is a balanced selective serotonin and norepinephrine-reuptake inhibitor available in the United States for the treatment of major depressive disorder (MDD) and diabetic ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT 1A agonist being developed ...

New research published in Annals of Family Medicine identifies five clinically relevant prescribing cascades in a national sample of more than half a million older adults in Ireland. The findings show ...

AD109 (Apnimed) is made up of 2.5 mg aroxybutynin, a novel antimuscarinic, and 75 mg atomoxetine, a selective norepinephrine reuptake inhibitor, according to a press release from Apnimed.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

The selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine are FDA approved for the treatment of PTSD. The serotonin norepinephrine reuptake inhibitor venlafaxine has also shown ...

When we think of the symptoms of major depressive disorder (MDD) we typically think of persistent feelings of sadness, lack ...

There is still a pressing need for antidepressant therapies that can start to work more quickly than current tricyclic or selective ... dopamine and norepinephrine reuptake inhibitor Sunosi ...

including benzodiazepine sedatives (such as Xanax), selective serotonin reuptake inhibitor (SSRI) antidepressants (such as Prozac), and serotonin and norepinephrine reuptake inhibitor (SNRI ...

In response to the FDA's feedback, Axsome plans to conduct an additional controlled trial that will use a fixed-dose paradigm ...

It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Their combined pharmacological synergy targets the ...